Who
Paul J. Lytle
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Actuate Therapeutics; EVP, Chief Financial Officer, Mosaic ImmunoEngineering; Chief Financial Officer, Peregrine Pharmaceuticals.
In numbers
- Trades disclosed
- 43
- Buys
- 3
- Sells
- 0
- Bought
- $25K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 15 Feb 2006
- Last trade
- 1 Apr 2026
- Last filed
- 1 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 1 Apr 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,394 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,899 at $0.00 | filing |
| 14 Aug 2024filed 14 Aug 2024 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —234,971 at $0.00 | filing |
| 29 Jan 2021filed 29 Jan 2021 | Mosaic ImmunoEngineering | SEC FORM 4 Code C | —1,641,252 | filing |
| 29 Jan 2021filed 29 Jan 2021 | Mosaic ImmunoEngineeringoption or derivative | SEC FORM 4 Code C | —161,000 | filing |
| 16 Dec 2020filed 16 Dec 2020 | Mosaic ImmunoEngineeringoption or derivative | SEC FORM 4 Code A | $140K42,392 at $3.30 | filing |
| 16 Dec 2020filed 16 Dec 2020 | Mosaic ImmunoEngineeringoption or derivative | SEC FORM 4 Code A | $125K37,772 at $3.30 | filing |
| 28 Apr 2017filed 28 Apr 2017 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $10K37,389 at $0.27 | filing |
| 31 Oct 2016filed 1 Nov 2016 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $9,79733,783 at $0.29 | filing |
| 2 Jun 2016filed 3 Jun 2016 | Peregrine Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 30 Oct 2015filed 2 Nov 2015 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $5,8506,158 at $0.95 | filing |
| 11 May 2015filed 12 May 2015 | Peregrine Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 30 Apr 2015filed 1 May 2015 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $5,7915,217 at $1.11 | filing |
| 6 May 2014filed 8 May 2014 | Peregrine Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 6 May 2013filed 8 May 2013 | Peregrine Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 30 Apr 2013filed 1 May 2013 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $8,51111,988 at $0.71 | filing |
| 27 Dec 2012filed 28 Dec 2012 | Peregrine Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 31 Oct 2012filed 1 Nov 2012 | Peregrine Pharmaceuticals | SEC FORM 4 Code J | $8,14520,885 at $0.39 | filing |
News
No headline names them, or the companies they trade most, lately.